Sulzer Medica, Remaining Independent, Contemplates Zimmer Buy
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of Bristol-Myers Squibb's Zimmer orthopedics business is under consideration by Sulzer Medica, but Sulzer cautions that "the purchase price and other terms of a possible transaction will play an important role in the decision," according to an Oct. 27 announcement.
You may also be interested in...
Sulzer Buys Paragon Anticipating Increased Conversion To Dental Implants
Anticipating increased conversion of the tooth replacement market to dental implants from conventional treatments such as bridges and crowns, Sulzer Medica is paying about 3.3 times sales to acquire dental implant maker Core Vent Corporation/Paragon Implant Company. The move roughly doubles Sulzer's share of the $550 mil. dental implant market to about 10.5%.
Sulzer Buys Paragon Anticipating Increased Conversion To Dental Implants
Anticipating increased conversion of the tooth replacement market to dental implants from conventional treatments such as bridges and crowns, Sulzer Medica is paying about 3.3 times sales to acquire dental implant maker Core Vent Corporation/Paragon Implant Company. The move roughly doubles Sulzer's share of the $550 mil. dental implant market to about 10.5%.
BMS Keeping ConvaTec, Cutting Zimmer: Matching Howmedica May Be Hard
Bristol-Myers Squibb's exit from non-pharmaceutical businesses will not include the divestiture of ConvaTec. BMS is retaining the wound management business with the goal of reversing the division's recent sluggish sales results.